A Phase II Study of Balstilimab Independently or in Combination With Zalifrelimab in Advanced Cervical Cancer
NCT ID: NCT05033132
Last Updated: 2024-03-28
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
WITHDRAWN
Clinical Phase
PHASE2
Study Classification
INTERVENTIONAL
Study Start Date
2021-10-01
Study Completion Date
2024-12-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This is an open-label, multi-center Phase II clinical trial to assess the efficacy, safety, and pharmacokinetics of Balstilimab (Treatment Arm 1 - monotherapy) or in combination with Zalifrelimab (Treatment Arm 2 - combination therapy) for treatment of patients with advanced cervical cancer who relapsed or progressed after receiving first-line platinum-based chemotherapy.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
BALSTILIMAB on Viral Clearance in HPV+ Oropharyngeal Cancer Patients
NCT05363709
HPV
Oropharyngeal Cancer
RECRUITING
PHASE2
A Phase II Clinical Study to Assess the Efficacy and Safety of IBI310 or Placebo Combined With Sintilimab for Advanced Cervical Cancer Subjects Who Have Failed or Cannot Tolerate First-line or Above Platinum-based Chemotherapy
NCT04590599
Advanced Cervical Cancer
COMPLETED
PHASE2
Zalutumumab in Combination With Radiotherapy in Head and Neck Cancer Patients Ineligible for Platinum Based Chemotherapy
NCT00707655
Head and Neck Cancer
Squamous Cell Carcinoma
TERMINATED
PHASE1/PHASE2
Zimberelimab Combined With Concurrent Radiotherapy and Chemotherapy for Locally Advanced Cervical Cancer
NCT05437692
Locally Advanced Cervical Cancer
UNKNOWN
PHASE2
Zalutumumab in Patients With Non-curable Head and Neck Cancer
NCT00382031
Head and Neck Cancer
Squamous Cell Cancer
COMPLETED
PHASE3
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Cervical Cancer
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Balstilimab
Balstilimab monotherapy: approximately 147 patients.
Group Type
EXPERIMENTAL
Balstilimab
Intervention Type
DRUG
Anti-programmed cell death protein 1 (anti-PD-1) monoclonal antibody
Balstilimab + Zalifrelimab
Balstilimab in combination with Zalifrelimab (combination therapy): approximately 30 patients.
Group Type
EXPERIMENTAL
Balstilimab + Zalifrelimab
Intervention Type
DRUG
An anti-PD-1 monoclonal antibody in combination with a cytotoxic T-lymphocyte antigen-4 (CTLA-4) antibody
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Balstilimab
Anti-programmed cell death protein 1 (anti-PD-1) monoclonal antibody
Intervention Type
DRUG
Balstilimab + Zalifrelimab
An anti-PD-1 monoclonal antibody in combination with a cytotoxic T-lymphocyte antigen-4 (CTLA-4) antibody
Intervention Type
DRUG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Voluntarily agree to participate by giving written informed consent.
* Diagnosis:
1. Have a histologically or cytologically confirmed, locally advanced, inoperable and/or metastatic cervical squamous cell carcinoma, cervical adenosquamous cell carcinoma or cervical adenocarcinoma. Note: A pathological report confirmed by histology or cytology of the primary tumor is required for definitive diagnosis. The following cervical tumors are not eligible for inclusion: minimal deviation adenocarcinoma, gastric-type endocervical adenocarcinoma, clear cell adenocarcinoma of the cervix, neuroendocrine carcinoma of the cervix and mesonephric adenocarcinoma.
2. Patients with recurrent/metastatic cervical cancer who have received at least 1 platinum-based systemic therapy (excluding radiosensitizing chemotherapy) (with or without bevacizumab), and experienced recurrence or progression of cervical cancer or were intolerable to chemotherapy toxicity during or after the systemic therapy and were unable to receive radiotherapy or radical surgery again. Note (definition of failure or intolerability of first-line platinum-based chemotherapy):
1. Patients with recurrent or metastatic cervical cancer who have experienced disease progression during platinum-based regimen or have experienced disease progression after receiving ≥4 cycles of effective platinum-based regimen (complete response/progressive disease/stable disease) or were intolerable to toxicity caused by platinum during/after platinum-based regimen and were not suitable for continuous platinum-based regimen.
Or
2. Patients with cervical cancer progressed or relapsed during neoadjuvant or adjuvant chemotherapy with platinum-based regimen (≥4 cycles if the platinum-based regimen is effective) or within 6 months after the end of the treatment, are deemed to have failed first-line platinum-based chemotherapy.
3. Programmed death-ligand 1 (PD-L1) positive (combined positive score ≥1).
* Have at least 1 measurable lesion on imaging based on RECIST 1.1. Measurable lesions should have not been treated with topical treatment such as radiotherapy. If the only one measurable lesion has been treated with previous topical treatment (radiotherapy, ablation, vascular intervention, etc.), it is necessary to confirm that the lesion has progressed, otherwise it will be recorded as a non-target lesion.
* Have a life expectancy of at least 3 months.
* Eastern Cooperative Oncology Group performance status of 0 or 1.
* Have satisfactory organ function as indicated by the following laboratory values:
1. Bone marrow: absolute neutrophil count \>1.5 × 10\^9/liter (L), platelet count \>100 × 10\^9/L, and hemoglobin \>8 grams (g)/deciliter (80 g/deciliter) (without transfusions of blood or blood component within 2 weeks of test);
2. Liver: serum total bilirubin (TBIL) level ≤1.5 × upper limit of normal (ULN), aspartate aminotransferase (AST) level ≤2.5 × ULN, alanine aminotransferase (ALT) level ≤2.5 × ULN (TBIL ≤1.5 × ULN, AST ≤5 × ULN, ALT ≤5 × ULN in case of presence of liver metastases);
3. Serum creatinine ≤1.5 × ULN; or endogenous creatinine clearance ≥50 milliliters/minute for serum creatinine \>1.5 × ULN;
4. Eligible coagulation function, defined as International Normalized Ratio and prothrombin time ≤1.5 x institutional upper limit of normal (IULN); and activated partial thromboplastin time ≤1.5 x IULN.
* No history of other malignancies within 5 years prior to first dose, except for basal cell carcinoma of the skin, superficial bladder cancer, and squamous cell carcinoma of the skin.
* Patient must provide an adequate amount of eligible formalin fixed paraffin-embedded tumor tissue samples, preferably from a recent tumor focus biopsy, or tumor tissue samples collected at or after the diagnosis of advanced or metastatic tumors from the site that has not been previously treated with radiation. If tumor tissue is not available, a tumor biopsy is required.
* Female patients with or without childbearing potential, for the former, the serum pregnancy test should be negative at the time of screening (serum pregnancy test is preferred within 7 days prior to first dose of the investigational drug, otherwise urine pregnancy test is acceptable if serum pregnancy test is not available). Female patients without childbearing potential are defined as follows (for reasons other than medication): ≥45 years of age and menopause for more than 1 year; post hysterectomy, post oophorectomy or post tubal ligation.
* Females of potential pregnancy must use a highly effective method of contraception (e.g., oral contraceptives, intrauterine devices, abstinence or barrier contraception combined with spermicide) throughout the study and continue contraception for 12 months after the end of treatment.
* Is willing and able to comply with the requirements of the protocol.
* Diagnosis:
1. Have a histologically or cytologically confirmed, locally advanced, inoperable and/or metastatic cervical squamous cell carcinoma, cervical adenosquamous cell carcinoma or cervical adenocarcinoma. Note: A pathological report confirmed by histology or cytology of the primary tumor is required for definitive diagnosis. The following cervical tumors are not eligible for inclusion: minimal deviation adenocarcinoma, gastric-type endocervical adenocarcinoma, clear cell adenocarcinoma of the cervix, neuroendocrine carcinoma of the cervix and mesonephric adenocarcinoma.
2. Patients with recurrent/metastatic cervical cancer who have received at least 1 platinum-based systemic therapy (excluding radiosensitizing chemotherapy) (with or without bevacizumab), and experienced recurrence or progression of cervical cancer or were intolerable to chemotherapy toxicity during or after the systemic therapy and were unable to receive radiotherapy or radical surgery again. Note (definition of failure or intolerability of first-line platinum-based chemotherapy):
1. Patients with recurrent or metastatic cervical cancer who have experienced disease progression during platinum-based regimen or have experienced disease progression after receiving ≥4 cycles of effective platinum-based regimen (complete response/progressive disease/stable disease) or were intolerable to toxicity caused by platinum during/after platinum-based regimen and were not suitable for continuous platinum-based regimen.
Or
2. Patients with cervical cancer progressed or relapsed during neoadjuvant or adjuvant chemotherapy with platinum-based regimen (≥4 cycles if the platinum-based regimen is effective) or within 6 months after the end of the treatment, are deemed to have failed first-line platinum-based chemotherapy.
3. Programmed death-ligand 1 (PD-L1) positive (combined positive score ≥1).
* Have at least 1 measurable lesion on imaging based on RECIST 1.1. Measurable lesions should have not been treated with topical treatment such as radiotherapy. If the only one measurable lesion has been treated with previous topical treatment (radiotherapy, ablation, vascular intervention, etc.), it is necessary to confirm that the lesion has progressed, otherwise it will be recorded as a non-target lesion.
* Have a life expectancy of at least 3 months.
* Eastern Cooperative Oncology Group performance status of 0 or 1.
* Have satisfactory organ function as indicated by the following laboratory values:
1. Bone marrow: absolute neutrophil count \>1.5 × 10\^9/liter (L), platelet count \>100 × 10\^9/L, and hemoglobin \>8 grams (g)/deciliter (80 g/deciliter) (without transfusions of blood or blood component within 2 weeks of test);
2. Liver: serum total bilirubin (TBIL) level ≤1.5 × upper limit of normal (ULN), aspartate aminotransferase (AST) level ≤2.5 × ULN, alanine aminotransferase (ALT) level ≤2.5 × ULN (TBIL ≤1.5 × ULN, AST ≤5 × ULN, ALT ≤5 × ULN in case of presence of liver metastases);
3. Serum creatinine ≤1.5 × ULN; or endogenous creatinine clearance ≥50 milliliters/minute for serum creatinine \>1.5 × ULN;
4. Eligible coagulation function, defined as International Normalized Ratio and prothrombin time ≤1.5 x institutional upper limit of normal (IULN); and activated partial thromboplastin time ≤1.5 x IULN.
* No history of other malignancies within 5 years prior to first dose, except for basal cell carcinoma of the skin, superficial bladder cancer, and squamous cell carcinoma of the skin.
* Patient must provide an adequate amount of eligible formalin fixed paraffin-embedded tumor tissue samples, preferably from a recent tumor focus biopsy, or tumor tissue samples collected at or after the diagnosis of advanced or metastatic tumors from the site that has not been previously treated with radiation. If tumor tissue is not available, a tumor biopsy is required.
* Female patients with or without childbearing potential, for the former, the serum pregnancy test should be negative at the time of screening (serum pregnancy test is preferred within 7 days prior to first dose of the investigational drug, otherwise urine pregnancy test is acceptable if serum pregnancy test is not available). Female patients without childbearing potential are defined as follows (for reasons other than medication): ≥45 years of age and menopause for more than 1 year; post hysterectomy, post oophorectomy or post tubal ligation.
* Females of potential pregnancy must use a highly effective method of contraception (e.g., oral contraceptives, intrauterine devices, abstinence or barrier contraception combined with spermicide) throughout the study and continue contraception for 12 months after the end of treatment.
* Is willing and able to comply with the requirements of the protocol.
Exclusion Criteria
* Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigation device within 4 weeks of the first dose of treatment.
* Has an inadequate washout period prior to first dose of study drug defined as: received systemic cytotoxic chemotherapy or biological therapy within 3 weeks before first dose; received radiation therapy within 3 weeks before first dose; experienced major surgical procedures within 4 weeks prior to the first dose.
* Has received prior therapy with any antibody/drug-targeting T-cell co-stimulatory proteins (immune checkpoints), including but not limited to PD-1, PD-L1, CTLA-4, lymphocyte-activation gene 3, therapeutic vaccines, etc.
* Have not recovered from the toxicity of their last systemic antineoplastic therapy to grade 1 or below as defined by National Cancer Institute - Common Terminology Criteria for Adverse Events (NCI-CTCAE) 5.0 prior to the first dose of the study. Note: Patients with sensory neuropathy or alopecia grade ≤2 are eligible.
* Is expected to require any other form of systemic or localized antineoplastic therapy while on trial (including maintenance therapy with another agent, radiation therapy, and/or surgical resection).
* Has known severe hypersensitivity reactions to fully human monoclonal antibodies (NCI-CTCAE 5.0 Grade ≥3).
* Received hematopoietic stimulating factor treatment within 14 days (≤14 days) before the first dose of the study drug, such as granulocyte colony-stimulating factor, erythropoietin, etc.
* Central nervous system tumors, brain metastases, or meningeal metastases are found prior to the first dose of the study drug. Note: Patients with brain metastases are eligible for the study when meeting the following requirements: brain metastases prove to be stable (patients are required to provide the most recent head imaging prior to the first dose, with previous head imaging at least 4 weeks apart, for the investigator to determine whether the brain metastases are stable by comparing the results of the two examinations); any neurological symptoms resulting from brain metastases or their treatment must have resolved or be maintainable to a minimal degree and the symptoms can be clinically determined to be sequelae of the treated lesion; brain metastases treated with steroids must not be treated with steroids for at least 4 weeks prior to the first dose.
* Treatment with systemic corticosteroids or any other form of systemic immunosuppression within 7 days (≤7 days) prior to the first dose of the study drug. Note: Combination with corticosteroids for the treatment of immune-related adverse events and prophylactic use of anticontras allergy medications are permitted during the study period; patients requiring daily corticosteroid replacement therapy, e.g., 5 to 7.5 milligrams daily doses of prednisone or equivalent doses of hydrocortisone and steroid therapy (topical, intraocular, intranasal inhalation routes only) may be enrolled in this study. Note: Patients with type 1diabetes, vitiligo, psoriasis, hypothyroidism, or hyperthyroid disease not requiring immunosuppressive treatment are eligible.
* Active autoimmune disease requiring systemic therapy within the past 2 years or history of autoimmune disease or syndrome requiring systemic steroids/immunosuppressive drugs, e.g., hypophysitis, colitis, hepatitis, nephritis, etc. Replacement therapy (e.g., thyroxine, insulin, physiologic corticosteroid replacement therapy for renal or pituitary insufficiency) is not considered systemic immunosuppressive therapy. Note: Patients with type I diabetes, vitiligo, psoriasis, hypo- or hyperthyroidism who do not require immunosuppressive therapy are eligible for the study.
* Has had an allogeneic tissue/solid organ transplant.
* History of interstitial lung disease or a history of pneumonia that has required oral or intravenous corticosteroids.
* Symptoms of an active infection requiring intravenous systemic therapy.
* Positive human immunodeficiency virus antibody or positive syphilis spirochete antibody and positive syphilis spirochete antibody titer test result (i.e., active syphilis infection).
* Presence of active hepatitis B, hepatitis C or tuberculosis. Active hepatitis B and C are defined as follows: active hepatitis B, positive for hepatitis B surface antigen with the hepatitis B virus deoxyribonucleic acid quantification result greater than the ULN; active hepatitis C, positive for hepatitis C antibody with the hepatitis C virus ribonucleic acid quantification result greater than the ULN.
* Has clinically significant (i.e., active) cardiovascular disease. Note: The following cases are observed within 6 months prior to the first dose: heart disease (Class III/IV congestive heart failure or heart block as defined by the New York Heart Association); deep vein thrombosis or pulmonary embolism; myocardial infarction; severe or unstable arrhythmias or angina pectoris; percutaneous coronary intervention, acute coronary syndromes, coronary artery bypass grafting; cerebrovascular accident, transient ischemic attack, cerebral embolism.
* Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the patient's participation for the full duration of the trial, or is not in the best interest of the patient to participate, in the opinion of the treating investigator.
* Has known mental illness that would interfere with compliance with the requirements of the trial.
* Has a history of substance abuse, alcoholism or other addictions.
* Legal incapacity or legal limitation of capacity.
* Has an inadequate washout period prior to first dose of study drug defined as: received systemic cytotoxic chemotherapy or biological therapy within 3 weeks before first dose; received radiation therapy within 3 weeks before first dose; experienced major surgical procedures within 4 weeks prior to the first dose.
* Has received prior therapy with any antibody/drug-targeting T-cell co-stimulatory proteins (immune checkpoints), including but not limited to PD-1, PD-L1, CTLA-4, lymphocyte-activation gene 3, therapeutic vaccines, etc.
* Have not recovered from the toxicity of their last systemic antineoplastic therapy to grade 1 or below as defined by National Cancer Institute - Common Terminology Criteria for Adverse Events (NCI-CTCAE) 5.0 prior to the first dose of the study. Note: Patients with sensory neuropathy or alopecia grade ≤2 are eligible.
* Is expected to require any other form of systemic or localized antineoplastic therapy while on trial (including maintenance therapy with another agent, radiation therapy, and/or surgical resection).
* Has known severe hypersensitivity reactions to fully human monoclonal antibodies (NCI-CTCAE 5.0 Grade ≥3).
* Received hematopoietic stimulating factor treatment within 14 days (≤14 days) before the first dose of the study drug, such as granulocyte colony-stimulating factor, erythropoietin, etc.
* Central nervous system tumors, brain metastases, or meningeal metastases are found prior to the first dose of the study drug. Note: Patients with brain metastases are eligible for the study when meeting the following requirements: brain metastases prove to be stable (patients are required to provide the most recent head imaging prior to the first dose, with previous head imaging at least 4 weeks apart, for the investigator to determine whether the brain metastases are stable by comparing the results of the two examinations); any neurological symptoms resulting from brain metastases or their treatment must have resolved or be maintainable to a minimal degree and the symptoms can be clinically determined to be sequelae of the treated lesion; brain metastases treated with steroids must not be treated with steroids for at least 4 weeks prior to the first dose.
* Treatment with systemic corticosteroids or any other form of systemic immunosuppression within 7 days (≤7 days) prior to the first dose of the study drug. Note: Combination with corticosteroids for the treatment of immune-related adverse events and prophylactic use of anticontras allergy medications are permitted during the study period; patients requiring daily corticosteroid replacement therapy, e.g., 5 to 7.5 milligrams daily doses of prednisone or equivalent doses of hydrocortisone and steroid therapy (topical, intraocular, intranasal inhalation routes only) may be enrolled in this study. Note: Patients with type 1diabetes, vitiligo, psoriasis, hypothyroidism, or hyperthyroid disease not requiring immunosuppressive treatment are eligible.
* Active autoimmune disease requiring systemic therapy within the past 2 years or history of autoimmune disease or syndrome requiring systemic steroids/immunosuppressive drugs, e.g., hypophysitis, colitis, hepatitis, nephritis, etc. Replacement therapy (e.g., thyroxine, insulin, physiologic corticosteroid replacement therapy for renal or pituitary insufficiency) is not considered systemic immunosuppressive therapy. Note: Patients with type I diabetes, vitiligo, psoriasis, hypo- or hyperthyroidism who do not require immunosuppressive therapy are eligible for the study.
* Has had an allogeneic tissue/solid organ transplant.
* History of interstitial lung disease or a history of pneumonia that has required oral or intravenous corticosteroids.
* Symptoms of an active infection requiring intravenous systemic therapy.
* Positive human immunodeficiency virus antibody or positive syphilis spirochete antibody and positive syphilis spirochete antibody titer test result (i.e., active syphilis infection).
* Presence of active hepatitis B, hepatitis C or tuberculosis. Active hepatitis B and C are defined as follows: active hepatitis B, positive for hepatitis B surface antigen with the hepatitis B virus deoxyribonucleic acid quantification result greater than the ULN; active hepatitis C, positive for hepatitis C antibody with the hepatitis C virus ribonucleic acid quantification result greater than the ULN.
* Has clinically significant (i.e., active) cardiovascular disease. Note: The following cases are observed within 6 months prior to the first dose: heart disease (Class III/IV congestive heart failure or heart block as defined by the New York Heart Association); deep vein thrombosis or pulmonary embolism; myocardial infarction; severe or unstable arrhythmias or angina pectoris; percutaneous coronary intervention, acute coronary syndromes, coronary artery bypass grafting; cerebrovascular accident, transient ischemic attack, cerebral embolism.
* Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the patient's participation for the full duration of the trial, or is not in the best interest of the patient to participate, in the opinion of the treating investigator.
* Has known mental illness that would interfere with compliance with the requirements of the trial.
* Has a history of substance abuse, alcoholism or other addictions.
* Legal incapacity or legal limitation of capacity.
Minimum Eligible Age
18 Years
Eligible Sex
FEMALE
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Betta Pharmaceuticals Co., Ltd.
INDUSTRY
Sponsor Role
collaborator
Agenus Inc.
INDUSTRY
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Director
Role: STUDY_DIRECTOR
Agenus Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Betta Clinical Study Site 4
Bengbu, Anhui, China
Site Status
Betta Clinical Study Site 2
Hefei, Anhui, China
Site Status
Betta Clinical Study Site 3
Hefei, Anhui, China
Site Status
Betta Clinical Study Site 27
Wuhu, Anhui, China
Site Status
National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
Beijing, Beijing Municipality, China
Site Status
Betta Clinical Study Site 25
Beijing, Beijing Municipality, China
Site Status
Betta Clinical Study Site 42
Chongqing, Chongqing Municipality, China
Site Status
Betta Clinical Study Site 9
Fuzhou, Fujian, China
Site Status
Betta Clinical Study Site 22
Xiamen, Fujian, China
Site Status
Betta Clinical Study Site 41
Lanzhou, Gansu, China
Site Status
Betta Clinical Study Site 39
Lanzhou, Gansu, China
Site Status
Betta Clinical Study Site 14
Huizhou, Guangdong, China
Site Status
Betta Clinical Study Site 18
Meizhou, Guangdong, China
Site Status
Betta Clinical Study Site 10
Zhanjiang, Guangdong, China
Site Status
Betta Clinical Study Site 11
Nanning, Guangxi, China
Site Status
Betta Clinical Study Site 5
Cangzhou, Hebei, China
Site Status
Betta Clinical Study Site 40
Harbin, Heilongjiang, China
Site Status
Betta Clinical Study Site 43
Wuhan, Hubei, China
Site Status
Betta Clinical Study Site 28
Wuhan, Hubei, China
Site Status
Betta Clinical Study Site 12
Wuhan, Hubei, China
Site Status
Betta Clinical Study Site 29
Wuhan, Hubei, China
Site Status
Betta Clinical Study Site 31
Xiangyang, Hubei, China
Site Status
Betta Clinical Study Site 6
Changde, Hunan, China
Site Status
Betta Clinical Study Site 36
Changsha, Hunan, China
Site Status
Betta Clinical Study Site 35
Changsha, Hunan, China
Site Status
Betta Clinical Study Site 13
Changsha, Hunan, China
Site Status
Betta Clinical Study Site 21
Nanjing, Jiangsu, China
Site Status
Betta Clinical Study Site 8
Nanjing, Jiangsu, China
Site Status
Betta Clinical Study Site 38
Ganzhou, Jiangxi, China
Site Status
Betta Clinical Study Site 19
Nanchang, Jiangxi, China
Site Status
Betta Clinical Study Site 20
Nanchang, Jiangxi, China
Site Status
Betta Clinical Study Site 24
Shangrao, Jiangxi, China
Site Status
Betta Clinical Study Site 16
Changchun, Jilin, China
Site Status
Betta Clinical Study Site 15
Changchun, Jilin, China
Site Status
Betta Clinical Study Site 7
Dalian, Liaoning, China
Site Status
Betta Clinical Study Site 34
Shenyang, Liaoning, China
Site Status
Betta Clinical Study Site 17
Shenyang, Liaoning, China
Site Status
Betta Clinical Study Site 30
Xi'an, Shaanxi, China
Site Status
Betta Clinical Study Site 23
Taiyuan, Shanxi, China
Site Status
Betta Clinical Study Site 26
Tianjin, Tianjin Municipality, China
Site Status
Betta Clinical Study Site 37
Tianjin, Tianjin Municipality, China
Site Status
Betta Clinical Study Site 32
Ürümqi, Xinjiang, China
Site Status
Betta Clinical Study Site 33
Hangzhou, Zhejiang, China
Site Status
Countries
Review the countries where the study has at least one active or historical site.
China
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
C-750-CN01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Cetuximab and Cisplatin in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
NCT00101192
COMPLETED
PHASE2
A Study of Sintilimab Combined With Concurrent Chemoradiation Therapy in Locally Advanced Cervical Cancer
NCT05105672
UNKNOWN
PHASE2
Clinical Study to Evaluate the Efficacy and Safety of Nab-Paclitaxel Combined With Cisplatin and Sintilimab in Neoadjuvant Treatment of Locally Advanced Cervical Cancer
NCT07088731
NOT_YET_RECRUITING
PHASE2
Adjuvant Chemoradiotherapy Followed by Zimberelimab for Locally Advanced Cervical Cancer.
NCT06128460
NOT_YET_RECRUITING
PHASE2
Pembrolizumab Plus Olaparib in Patients With Recurrent Cervical Cancer
NCT04641728
UNKNOWN
PHASE2
Clinical Study of Albumin-bound Paclitaxel Plus Nedaplatin in Cervical Cancer
NCT01667211
UNKNOWN
PHASE2
Patritumab With Cetuximab and a Platinum Containing Therapy for Patients With Head and Neck Cancer
NCT02350712
COMPLETED
PHASE1
Balstilimab Versus Investigator Choice Chemotherapy in Patients With Recurrent Cervical Cancer (BRAVA)
NCT04943627
WITHDRAWN
PHASE3
Carboplatin-Paclitaxel Adjuvant Chemotherapy in the Treatment of Locally Advanced Cervical Cancer
NCT04016142
TERMINATED
PHASE2
A Study of RC48-ADC Combination With Zimberelimab Injection Therapies at Least First-line Platinum-containing Standard Therapy Failed With Recurrent or Metastatic Cervical Cancer
NCT06155396
RECRUITING
PHASE2
Cisplatin and Radiation Therapy Followed by Paclitaxel and Carboplatin in Treating Patients With Stage IB-IVA Cervical Cancer
NCT01295502
UNKNOWN
PHASE1
Cetuximab Plus Cisplatin in Treating Patients With Metastatic or Recurrent Cancer of the Head and Neck That Has Not Responded to Cisplatin Chemotherapy
NCT00004865
COMPLETED
PHASE2
A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Recurrent or Metastatic Cervical Cancer and Other Gynecological Malignancies
NCT05990803
RECRUITING
PHASE2
Study of ZG005 in Combination With Paclitaxel＋Platinum-based ± Bevacizumab in Patients With Advanced Cervical Carcinoma
NCT06241235
RECRUITING
PHASE1/PHASE2
Zimberelimab Combined With Albumin-bound Paclitaxel and Cisplatin in Neoadjuvant Treatment of LACC
NCT06055738
RECRUITING
PHASE2
Paclitaxel and Carboplatin Followed by Cisplatin and Radiation Therapy in Treating Patients With Stage IB, Stage II, Stage III, or Stage IVA Cervical Cancer
NCT00462397
UNKNOWN
PHASE2
S9717 Tirapazamine Plus Cisplatin in Treating Patients With Metastatic, Recurrent, or Refractory Cervical Cancer
NCT00003369
COMPLETED
PHASE2
Neoadjuvant Immunochemotherapy for Locally Advanced Cervical Cancer: a Prospective, Single-arm, Phase II Clinical Trial
NCT07003620
RECRUITING
PHASE2
Comparative Study of Gemcitabine,Cisplatin and Radiation Versus Cisplatin and Radiation in Cancer of the Cervix
NCT00191100
COMPLETED
PHASE3
Phase II Clinical Trial of Concurrent Chemoradiotherapy Combined Nimotuzumab for Stage IIB-IVA Cervical Cancer
NCT02705612
UNKNOWN
PHASE2
Zalutumumab in Combination With Chemotherapy and Radiotherapy in Head and Neck Cancer
NCT00401401
TERMINATED
PHASE1/PHASE2
Platinum Chemotherapy Plus Paclitaxel With Bevacizumab and Atezolizumab in Metastatic Carcinoma of the Cervix
NCT03556839
ACTIVE_NOT_RECRUITING
PHASE3
Induction Chemotherapy Followed By Cetuximab and Radiation in HPV-Associated Resectable Stage III/IV Oropharynx Cancer
NCT01084083
COMPLETED
PHASE2
A Phase II Study of Serplulimab Plus Bevacizumab in Combination With Chemotherapy in 1L Treatment of Untreated Recurrent or Metastatic Cervical Cancer
NCT05444374
NOT_YET_RECRUITING
PHASE2